All In Biotech

Drug Trial Radar · NCT05903092

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) for tReatmenT of Small Cell Lung Cancer (MOZART)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Sep 26, 2023

Primary completion

Oct 31, 2029

Study completion Oct 31, 2030

Sponsor

Lead sponsor
Khalil ChoucairAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AstraZeneca; Barbara Ann Karmanos Cancer Institute
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, subjects will continue maintenance treatment with durvalumab plus monalizumab every 4 weeks until disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal of consent. Patients who have received one prior cycle of treatment before enrolling on the study will receive a total of 4 cycles with monalizumab, durvalumab, and chemotherapy. There will be a safety lead-in phase, including 6 to 12 patients, to confirm the safety of the proposed dose of monalizumab to use in combination with chemotherapy and durvalumab. MOZART-LS cohort: Study treatment will consist of durvalumab and monalizumab following standard of care chemo-radiation consisting of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide for 3-4 cycles and standard dose radiation. Radiation therapy should have started before completion of cycle 2 of chemotherapy. NOTE: Subjects who have non-progressive disease and meet the eligibility criteria can start study treatment up to 56 days from completion of chemo-radiation. Durvalumab and monalizumab will be administered every 4 weeks for up to 2 years (26 cycles), disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal consent, whichever occurs first.

Conditions

  • Small Cell Lung Cancer
  • SCLC
  • Extensive Stage Small Cell Lung Cancer
  • Limited Stage Small-Cell Lung Cancer

Interventions

  • DurvalumabDrug

    1500mg IV on Day 1 of every Cycle

  • MonalizumabDrug

    1500mg IV on Day 1 of every Cycle

  • Carboplatin or CisplatinDrug

    On Day 1 of Cycles 1-4 by IV: Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2

  • EtoposideDrug

    80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1 year Progression Free Survival (PFS)Time frame: 1 year
  2. Safety and TolerabilityTime frame: 24 Months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Karmanos Cancer Center (Wayne State University)

    Detroit, Michigan · Recruiting

  • University of Virginia Health System

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.